Caie Wang, Yiyang Shang, Ghid Kanaan, Lu Chai, Hui Li, Xingshun Qi | Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a major public health challenge, with approximately 32.4% of adults globally diagnosed with the condition and a steadily increasing prevalence. Currently, no specific medicines are approved to manage MASLD effectively. Silymarin, a common herbal agent with antioxidant, anti‐inflammatory, and antifibrotic properties, presents potential therapeutic benefits for MASLD in both its monotherapy and complex forms (complexation with solubilising agents, such as vitamin E, phosphatidyl choline, etc.). https://doi.org/10.1002/14651858.CD015524.pub2